These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 26498005)
1. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Hansen GL; Gaudernack G; Brunsvig PF; Cvancarova M; Kyte JA Cancer Immunol Immunother; 2015 Dec; 64(12):1609-21. PubMed ID: 26498005 [TBL] [Abstract][Full Text] [Related]
2. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169 [TBL] [Abstract][Full Text] [Related]
3. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084 [TBL] [Abstract][Full Text] [Related]
4. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401 [TBL] [Abstract][Full Text] [Related]
5. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215 [TBL] [Abstract][Full Text] [Related]
6. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Kyte JA; Gaudernack G; Dueland S; Trachsel S; Julsrud L; Aamdal S Clin Cancer Res; 2011 Jul; 17(13):4568-80. PubMed ID: 21586625 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM Front Immunol; 2020; 11():572172. PubMed ID: 33324397 [TBL] [Abstract][Full Text] [Related]
8. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report. Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM Front Immunol; 2018; 9():2145. PubMed ID: 30283461 [No Abstract] [Full Text] [Related]
9. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148 [TBL] [Abstract][Full Text] [Related]
10. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer. Iversen TZ Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457 [TBL] [Abstract][Full Text] [Related]
11. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435 [TBL] [Abstract][Full Text] [Related]
12. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer. Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189 [TBL] [Abstract][Full Text] [Related]
13. Elevated Circulating CD4 Hu X; Gu Y; Zhao S; Hua S; Jiang Y Cancer Biother Radiopharm; 2019 Jun; 34(5):325-333. PubMed ID: 30925076 [No Abstract] [Full Text] [Related]
14. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317 [TBL] [Abstract][Full Text] [Related]
15. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer. Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695 [TBL] [Abstract][Full Text] [Related]
16. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077 [TBL] [Abstract][Full Text] [Related]
17. Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study. Adotévi O; Vernerey D; Jacoulet P; Meurisse A; Laheurte C; Almotlak H; Jacquin M; Kaulek V; Boullerot L; Malfroy M; Orillard E; Eberst G; Lagrange A; Favier L; Gainet-Brun M; Doucet L; Teixeira L; Ghrieb Z; Clairet AL; Guillaume Y; Kroemer M; Hocquet D; Moltenis M; Limat S; Quoix E; Mascaux C; Debieuvre D; Fagnoni-Legat C; Borg C; Westeel V J Clin Oncol; 2023 Jan; 41(2):373-384. PubMed ID: 36070539 [TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients. Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270 [TBL] [Abstract][Full Text] [Related]
19. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC. Song H; Liu S; Zhao Z; Sun W; Wei X; Ma X; Zhao P; Gao D Int Immunopharmacol; 2017 Nov; 52():197-202. PubMed ID: 28941416 [TBL] [Abstract][Full Text] [Related]
20. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. Greten TF; Forner A; Korangy F; N'Kontchou G; Barget N; Ayuso C; Ormandy LA; Manns MP; Beaugrand M; Bruix J BMC Cancer; 2010 May; 10():209. PubMed ID: 20478057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]